login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

Satisfactory results with endovenous laser ablation 6.5 years after treatment


Thursday, 10 May 2012 14:27
Michael Gough
Michael Gough


Michael Gough, Leeds General Infirmary, Leeds, UK, presented long-term follow-up after endovenous laser ablation for great saphenous varicose veins at the 34th Charing Cross International Symposium in London, UK. The study reviewed a group of 63 patients (79 limbs) 6.5 years after above-knee laser treatment.


“Current techniques for endovenous ablation have changed, but at the time we were only ablating the above-knee great saphenous vein regardless of whether there was above- and below-knee reflux or not. The follow-up was done with ultrasound, Aberdeen Varicose Vein Severity Score (AVVSS) and CEAP grade,” Gough said.

He told delegates that the ultrasound findings showed “very satisfactory” results in the reduction of full above-knee great saphenous vein reflux and groin neovascularisation.


“The commonest abnormality was persistent below-knee reflux. Nowadays that is easily dealt with because we would always ablate an incompetent below-knee great saphenous vein at the initial treatment. So that is not a problem. However, we did find that quite a few patients presented with segmental great saphenous vein reflux or with reflux at the sapheno-femoral junction. These patients are more problematic” he noted.


In terms of varicose vein reflux, the ultrasound results showed that 53% of limbs (42/79) had recurrent incompetence. When looking at patients, the recurrent varicose vein rate was lower, with 33% (21/63) reporting their presence. Seventy three per cent of the patients (45/62) considered the treatment successful and 80.6% (50/62) would have endovenous laser treatment again.


“In terms of the ultrasound recurrence, why had patients developed recurrent varicose veins? Most of them were because of progressive disease such as perforators, below-knee reflux, anterior or posterior thigh vein or pelvic varicosities. Nevertheless, a proportion were due to a failure of the original treatment,” Gough said.


He added that, despite that, quality of life improvements persisted at six years. “So when we take into consideration patients’ views on their recurrence and on repeat treatment, we have quite satisfactory results,” he stated. “Most recurrences were due to progressive disease, and two-thirds of these were suitable to further endovenous therapy. Neovascularisation, as we always suspected, was much less (14%) than with an equivalent group after surgery (54%) at five years.


The improvement in CEAP grade and quality of life was maintained.


“Persistent below-knee reflux was the commonest finding and we now treat it from the outset as we know that it reduces the risk of residual varicose veins after the initial treatment. As far as the group with segmental reflux and sapheno-femoral junction reflux is concerned, it is tempting to suggest that a 1470nm radial fibre may reduce the risk of this happening but of course we have to await further data.”




Add New Comment

Most popular


Incraft low-profile endograft launched in Europe and Canada
Wednesday, 10 Sep 2014
Cordis announced on 10 September the launch of its Incraft AAA Stent Graft System, an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from ... Incraft low-profile endograft launched in Europe and Canada

First patient enrolled in US study of Novate’s Sentry IVC filter
Monday, 22 Sep 2014
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE ... First patient enrolled in US study of Novate’s Sentry IVC filter

First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA

Features


Not all drug-eluting balloons are equal
Wednesday, 15 Oct 2014
Thomas Zeller, Bad Krozingen, Germany, analyses the results of two recent randomised controlled trials comparing drug-eluting balloons to angioplasty alone in femoropopliteal lesions. Not all drug-eluting balloons are equal

Renal stenting may benefit patients excluded from randomised trials, says expert consensus
Wednesday, 15 Oct 2014
Sahil A Parikh, Case Western Reserve University School of Medicine, Cleveland, USA, speaks to Vascular News about the Society for Cardiovascular Angiography and Interventions expert consensus on ... Renal stenting may benefit patients excluded from randomised trials, says expert consensus

Profiles


Martin Björck
Wednesday, 01 Oct 2014
Martin Björck, Uppsala University Hospital, Sweden, holds the only professor-chair of vascular ... Martin Björck

Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions